SynthesisMedicine2025
Diagnostic value of pyruvate kinase isoenzyme type M2 for colorectal cancer: Evidence from meta-analysis.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis meta-analysis is to objectively and comprehensively evaluate the diagnostic value of pyruvate kinase isoenzyme type M2 (M2-PK) in colorectal cancer (CRC).
methodsAll studies on the diagnostic value of M2-PK for CRC were retrieved from the PubMed, WanFang, CNKI, MEDLINE, Web of Science, and CBM databases until February 2020. Data were extracted from studies conforming to the inclusion and exclusion criteria. The sensitivity and specificity data were pooled. For heterogeneity analysis, subgroup analysis was performed according to race, test method, sample type, and tumor staging. The Stata 16.0 was used to conduct the statistical analysis.
resultsAbout 27 studies were included: 1821 cases in the case group and 3406 cases in the control group. The results showed that the pooled sensitivity and specificity of M2-PK for diagnosing CRC were 77% (95% CI: 73%-81%) and 83% (95% CI: 78%-87%), and the area under the ROC curve was 87% (95%CI: 83%-89%).
conclusionThis meta-analysis showed that M2-PK has a relatively high sensitivity and specificity for diagnosing CRC and has a higher diagnostic value in early diagnosis of CRC. However high-quality prospective studies are required to confirm its diagnostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.